ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

Dept. of Defense opens program announcements for prostate cancer research.

December 10, 2004

DCT Board Approves Concepts Of Five Contract Recompetitions

October 14, 1983

Panel Angered By Unreasonable Senate Committee Demands, Will Seek Meeting With Hatch On Probe

April 24, 1981

Pre-Emptive Treatment Helped Curtail Panitumumab Toxicity

January 30, 2009

NCI News: Communications Office Seeks Partners for Education Programs

October 11, 1996

Biotech Firm Plans Custom Clinical trials In USSR for Drug Firms

August 18, 1989